Literature DB >> 15450941

Inhibition of repair of carboplatin-induced DNA damage by 9-beta-D-arabinofuranosyl-2-fluoroadenine in quiescent human lymphocytes.

Kazutaka Takagi1, Yasukazu Kawai, Takahiro Yamauchi, Takanori Ueda.   

Abstract

Previous studies including ours have demonstrated that DNA repair is one of the important targets of fludarabine. The aim of this study is to clarify a mechanistic interaction of carboplatin and F-ara-A, from the perspective of F-ara-A-mediated inhibition of DNA repair initiated by carboplatin. Using human quiescent lymphocytes, we focused on DNA repair, since these cells provide a model of dormant cells. To evaluate the carboplatin-induced DNA incision and its repair, we used the alkaline comet assay. When lymphocytes were incubated with carboplatin, a dose-dependent increase in the tail-moment was observed. Then, tail-moment decreased in proportion to the incubation period in fresh media and recovered to the control level at 4 h. DNA rejoining was completely inhibited by F-ara-A at 10 microM through 0 to 6 h after washing out of these drugs and this F-ara-A-induced inhibition was concentration-dependent. Cellular damage after drug exposure was evaluated with the induction of apoptosis as well as cytotoxic effect. Exposure to carboplatin alone did not induce any apparent cellular damage in quiescent lymphocytes. In contrast, a more than additive induction of apoptosis as well as an enhancement of cytotoxic action was observed in cells treated with a combination of carboplatin and F-ara-A. In the CEM cell line, there was no enhancement of the cytotoxic action of these drugs, despite the clear demonstration of an inhibitory effect on DNA repair. These results indicate that chemotherapy with carboplatin opened a new target for F-ara-A by initiating DNA repair in quiescent cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450941     DOI: 10.1016/j.bcp.2004.06.027

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues.

Authors:  Nobuyuki Yoshio; Yasukazu Kawai; Hiroki Hori; Takanori Ueda
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Synergistic effects of combination with fludarabine and carboplatin depend on fludarabine-mediated inhibition of enhanced nucleotide excision repair in leukemia.

Authors:  Kazutaka Takagi; Yasukazu Kawai; Takahiro Yamauchi; Hiromichi Iwasaki; Takanori Ueda
Journal:  Int J Hematol       Date:  2011-09-23       Impact factor: 2.490

3.  Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal.

Authors:  Mazin A Moufarij; Deepa Sampath; Michael J Keating; William Plunkett
Journal:  Blood       Date:  2006-09-05       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.